We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 7
Most popular |Most recent

2015 Biometer Shows Tale of Two Markets

USA - May 16 2016 The full-year 2015 BioMeter paints the picture of a strong year for biotechnology, but deeper analysis shows a cautionary trend. The average BioMeter...

Allison Lauterbach Dale, Stephen B. Thau.

Record 2014 BioMeter shows strong year for biotech

USA - April 29 2015 The full-year 2014 BioMeter confirms that 2014 was a banner year for biotechnology. The average BioMeter value for the entire year across all...

Stephen B. Thau.

Q3 BioMeter shows reemergence of late stage deals

USA - October 27 2014 The average BioMeter value in the third quarter of 2014 was $43.7 million, an increase from the $30.4 million value in thesame quarter in 2013, and a...

Stephen B. Thau.

Q2 BioMeter shows strong value in drug discovery platforms

USA - August 7 2014 The average BioMeter value in the second quarter of 2014 jumped significantly to $143.4 million, an increase from the $15.9 million value in the...

Stephen B. Thau.

Early stage deals dominate Q1 - uptick in total dealmaking activity compared with same quarter last year

USA - May 13 2014 The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total...

Stephen B. Thau.